Bayer Yakuhin and Fuji Film RI Pharma Jointly Market Lymphoma Drug
This article was originally published in PharmAsia News
Executive SummaryOsaka-based Bayer Yakuhin, a subsidiary of Bayer Healthcare and Tokyo-based Fuji Film RI Pharma, a subsidiary of Fuji Film announced August 4 to jointly market Sevorin, a B-cell non-Hodgkin's lymphoma drug. (Click here for more - Japanese language) "Bayer Yakuhin and Fuji Film Subsidiary Jointly Market Lymphoma Drug And Start Taking Orders" - Jiji Press (8/4/08)
You may also be interested in...
ConMed’s ambitions in orthopedics are to be the clinician’s support, develop differentiated offerings and avoid “me too” activity, before all notions of leading the market rankings.
Executives On The Move: Tech And Science Announcements At Orexo And Agios, And Board Changes At Accorda And RhoVac
Swedish pharma Orexo welcomes EVP, digital health and anti-cancer therapeutics firm Agios Pharmaceuticals announces Bristol-Myers Squibb exec as its next CSO. And a chair takes a seat at Accorda Therapeutics and RhoVac.
In 2018, the top 100 publicly listed and reportable medical device technology companies had global sales spanning from over $30bn to some $100m in the lower reaches. As the latest In Vivo Medtech 100 ranking shows, many of the major changes in value sales were linked to company restructurings. But there were some impressive organic gains too.